Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 11:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: diltiazem Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2623091 in Healthy Participants

NCT02300259
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2623091, Itraconazole, Simvastatin, Tadalafil, Diltiazem
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)

NCT06703463
View directory record Official record
Conditions
Healthy
Interventions
MK-1167, Diltiazem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

NCT02010970
View directory record Official record
Conditions
Healthy Volunteers, Pharmacologic Action
Interventions
Group 1 AZD3293, Group 2 AZD3293, Group 3 AZD3293, Group 1 Itraconazole, Group 2 Diltiazem, Group 3 Midazolam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 4 Interventional Results available

Ranolazine and Microvascular Angina by PET in the Emergency Department

NCT02052011
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
30 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 23, 2026, 11:07 PM EDT
Recruiting Phase 4 Interventional

Adenosine vs Diltiazem for Treatment of SVT in the ED

NCT06993038
View directory record Official record
Conditions
Supraventricular Tachycardia (SVT)
Interventions
adenosine, diltiazem
Drug
Lead sponsor
Anne E. Zepeski
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

NCT02922452
View directory record Official record
Conditions
Ischemic Stroke
Interventions
BMS-986141, Dilitazem
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 23, 2026, 11:07 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 2Phase 3 Interventional

African American Study of Kidney Disease and Hypertension ABPM Pilot Study

NCT00582777
View directory record Official record
Conditions
Hypertensive Renal Disease
Interventions
USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2012 · Synced Sep 23, 2026, 11:07 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

NCT04130438
View directory record Official record
Conditions
Myocardial Bridging
Interventions
Nebivolol, Diltiazem, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics

NCT00645463
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 16, 2009 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)

NCT00803634
View directory record Official record
Conditions
Hypertension, Heart Failure
Interventions
Clevidipine, Standard of Care IV antihypertensive
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Montgomery, Alabama • Inglewood, California • Baton Rouge, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Sep 23, 2026, 11:07 PM EDT
Not listed Phase 1 Interventional

Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor

NCT05745337
View directory record Official record
Conditions
Atrial Fibrillation, Diastolic Dysfunction, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 23, 2026, 11:07 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

NCT01821274
View directory record Official record
Conditions
Skin Irritation
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution o sodium lauryl sulfate (SLS), Saline 0.9%
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers

NCT00318201
View directory record Official record
Conditions
Healthy
Interventions
Erythromycin, Diltiazem
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Diltiazem on Pharmacokinetics of BMS-914392

NCT01211808
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
BMS-914832, Diltiazem
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)

NCT06818968
View directory record Official record
Conditions
Healthy
Interventions
MK-6916, Diltiazem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem

NCT00319982
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Diltiazem, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
5 Years to 39 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants

NCT05162222
View directory record Official record
Conditions
Healthy Participants
Interventions
Danicamtiv, Itraconazole, Diltiazem
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 2

NCT00733239
View directory record Official record
Conditions
Opioid Dependence
Interventions
2-4 of the drugs listed below
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CiPA Phase 1 ECG Biomarker Validation Study

NCT03070470
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 23, 2026, 11:07 PM EDT
Not yet recruiting No phase listed Observational

Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control

NCT06783868
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Catheter Ablation, Market-approved AVNB, OAC and AAD
Device · Drug
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Overland Park, Kansas • Independence, Missouri • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 23, 2026, 11:07 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)

NCT07697625
View directory record Official record
Conditions
Healthy
Interventions
MK-4082, Diltiazem, Rescue medication
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects

NCT02080780
View directory record Official record
Conditions
CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction]
Interventions
Clarithromycin XL, 2% Diltiazem
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Sep 23, 2026, 11:07 PM EDT
Completed Phase 4 Interventional Results available

Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate

NCT05661942
View directory record Official record
Conditions
Atrial Fibrillation With Rapid Ventricular Response, Hypotension Drug-Induced
Interventions
Calcium pre-treatment, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 23, 2026, 11:07 PM EDT